Literature DB >> 11825987

Antibiotic resistance of Helicobacter pylori strains in Japanese children.

Seiichi Kato1, Shigeru Fujimura, Hirokazu Udagawa, Toshiaki Shimizu, Shunichi Maisawa, Kyoko Ozawa, Kazuie Iinuma.   

Abstract

The resistance of Helicobacter pylori to the recently available antibiotic treatment regimens has been a growing problem. We investigated the prevalence of H. pylori resistance to clarithromycin, metronidazole, and amoxicillin among 51 H. pylori isolates from Japanese children. In addition, the mutations of the corresponding gene were studied by PCR and restriction fragment length polymorphism analysis. Primary resistance to clarithromycin, metronidazole, and amoxicillin was detected in 29, 24, and 0% of strains, respectively. The eradication rates in clarithromycin-susceptible and -resistant strains were 89 and 56%, respectively (P < 0.05). The prevalence of strains with acquired resistance to clarithromycin (78%) was higher than that of strains with primary resistance (P < 0.01). Among the clarithromycin-resistant strains studied, 92% showed cross-resistance to azithromycin. No acquired resistance to amoxicillin was demonstrated. The A2144G mutation in the 23S rRNA gene was detected in 11 of 12 (92%) clarithromycin-resistant strains tested, whereas the mutation was not detected in any of the 15 susceptible strains. The deletion of the rdxA gene was not demonstrated in any of the strains. The results indicate that a high prevalence of clarithromycin-resistant strains is associated with eradication failure. Testing of susceptibility to clarithromycin is recommended.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11825987      PMCID: PMC153406          DOI: 10.1128/JCM.40.2.649-653.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Successful development of air-dried microplates (HP-Plates) for susceptibility testing against Helicobacter pylori isolates.

Authors:  Y Kawakami; T Akahane; A Gotoh; Y Okimura; K Oana; T Katsuyama
Journal:  Microbiol Immunol       Date:  1997       Impact factor: 1.955

2.  A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori.

Authors:  G G Stone; D Shortridge; J Versalovic; J Beyer; R K Flamm; D Y Graham; A T Ghoneim; S K Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

3.  Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance.

Authors:  J Versalovic; M S Osato; K Spakovsky; M P Dore; R Reddy; G G Stone; D Shortridge; R K Flamm; S K Tanaka; D Y Graham
Journal:  J Antimicrob Chemother       Date:  1997-08       Impact factor: 5.790

4.  Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents.

Authors:  R Piccolomini; G Di Bonaventura; G Catamo; F Carbone; M Neri
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

5.  Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome.

Authors:  R J Adamek; S Suerbaum; B Pfaffenbach; W Opferkuch
Journal:  Am J Gastroenterol       Date:  1998-03       Impact factor: 10.864

6.  Molecular typing of Helicobacter pylori isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism.

Authors:  V D Shortridge; G G Stone; R K Flamm; J Beyer; J Versalovic; D W Graham; S K Tanaka
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

7.  Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy.

Authors:  A Gotoh; Y Kawakami; T Akahane; T Akamatsu; T Shimizu; K Kiyosawa; T Katsuyama
Journal:  Microbiol Immunol       Date:  1997       Impact factor: 1.955

8.  Simultaneous colonisation of Helicobacter pylori with and without mutations in the 23S rRNA gene in patients with no history of clarithromycin exposure.

Authors:  M Matsuoka; Y Yoshida; K Hayakawa; S Fukuchi; K Sugano
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

9.  Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study.

Authors:  T Lind; S Veldhuyzen van Zanten; P Unge; R Spiller; E Bayerdörffer; C O'Morain; K D Bardhan; M Bradette; N Chiba; M Wrangstadh; C Cederberg; J P Idström
Journal:  Helicobacter       Date:  1996-09       Impact factor: 5.753

10.  Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

Authors:  J Versalovic; D Shortridge; K Kibler; M V Griffy; J Beyer; R K Flamm; S K Tanaka; D Y Graham; M F Go
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more
  24 in total

1.  T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh.

Authors:  Rasel Khan; Shamsun Nahar; Jinath Sultana; Mian Mashhud Ahmad; Motiur Rahman
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia.

Authors:  Alba A Trespalacios; William Otero; Jorge E Caminos; Marcela M Mercado; Jenny Avila; Liliana E Rosero; Azucena Arévalo; Raúl A Poutou-Piñales; David Y Graham
Journal:  J Microbiol       Date:  2013-08-30       Impact factor: 3.422

3.  Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy.

Authors:  Lian Zhang; Lin Shen; Jun-Ling Ma; Kai-Feng Pan; Wei-Dong Liu; Jie Li; Shu-Dong Xiao; San-Ren Lin; Meinhard Classen; Wei-Cheng You
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

4.  Antibiotic resistance of Helicobacter pylori in pediatric patients -- 10 years' experience.

Authors:  Iva Hojsak; Tea Kos; Jelena Dumančić; Zrinjka Mišak; Oleg Jadrešin; Alemka Jaklin Kekez; Amarela Lukić Grlić; Sanja Kolaček
Journal:  Eur J Pediatr       Date:  2012-03-20       Impact factor: 3.183

5.  Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors.

Authors:  Jed W Fahey; Xavier Haristoy; Patrick M Dolan; Thomas W Kensler; Isabelle Scholtus; Katherine K Stephenson; Paul Talalay; Alain Lozniewski
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

6.  Characterisation of the genes encoding resistance to metronidazole (rdxA and frxA) and clarithromycin (the 23S-rRNA genes) in South African isolates of Helicobacter pylori.

Authors:  N F Tanih; L M Ndip; R N Ndip
Journal:  Ann Trop Med Parasitol       Date:  2011-04

7.  Characterization of clarithromycin resistance in isolates of Helicobacter pylori from the UAE.

Authors:  Mubarak S Alfaresi; Abida A Elkoush
Journal:  Indian J Gastroenterol       Date:  2010-07-25

8.  Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium.

Authors:  V Y Miendje Deyi; V Y Miendje Deyi; P Bontems; J Vanderpas; E De Koster; R Ntounda; C Van den Borre; S Cadranel; A Burette
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

9.  Clarithromycin resistance among Helicobacter pylori strains isolated from children: prevalence and study of mechanism of resistance by PCR-restriction fragment length polymorphism analysis.

Authors:  Teresa Alarcón; Alba E Vega; Diego Domingo; Maria Josefa Martínez; Manuel López-Brea
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

10.  Primary Antibiotic Resistance to Helicobacter pylori Strains Isolated From Children in Northern Iran: A Single Center Study.

Authors:  Shohreh Maleknejad; Ali Mojtahedi; Afshin Safaei-Asl; Zeinab Taghavi; Ehsan Kazemnejad
Journal:  Iran J Pediatr       Date:  2015-12-23       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.